As a medical student taking care of cancer patients in 1990, Dr. James Hsieh witnessed the hopelessness metastatic cancer patients faced and decided to devote his life to the fight against cancer. His Ph.D. thesis concluded the mechanisms by which EBV EBNA2 hijacks Notch signaling for tumorigenesis and earned him the Young Investigator Award at Johns Hopkins Medical School in 1996. Dr. Hsieh entered Washington University for Internal Medicine and DFCI for Oncology training. Dr. Hsieh studied under the late Dr. Korsmeyer in 2000 as an HHMI Physician-Scientist Fellowship Awardee. He discovered proteolytic processing of MLL, purified the protease, and named it “Taspase1” in 2003. As NCI K01 Howard Temin Awardee, Dr. Hsieh joined the faculty at Wash U. in 2004. Dr. Hsieh was inducted into ASCI in 2010. As a physician scientist taking care of metastatic kidney cancer patients, Dr. Hsieh joined MSKCC to integrate his research and clinical interests in 2010, and founded the Translational Kidney Cancer Research Program (TKCRP) in 2011 to enable seamless collaboration among basic, preclinical, and clinical scientists. His team employs state-of-art platforms and clinical trial materials to integrate kidney cancer genomics, transcriptomics, proteomics, metabolomics, and therapeutics. His group pioneers a novel metabolic analytic algorithm (Metabologram) to interrogate human cancer metabolism in 2016. His laboratory recently established novel kidney cancer mouse models that recapitulate prevalent human kidney cancer mutations. Through studying kidney cancer, Dr. Hsieh proposed a novel cancer evolution (Braided Cancer River) model in 2015, capitalizing phenotypically, mechanistically convergent events to guide effective cancer therapy and overcome treatment-resistance. He was recruited back to Washington University in 2017. His primary translational goals are to develop novel mechanism-based, personalized therapeutics to prevent recurrence in high-risk patients and provide cure to significant number of metastatic kidney cancer patients.